- Enhanced dosimetry software for wider clinical use
- Support for new radionuclides
- Improved quantitative imaging and dosiomics
- Validated and quality-assured dosimetry workflows
"We are very proud to be one of the consortium members, together with diverse world-class partners, to propel forward this unique and ambitious Thera4Care project and driven precision healthcare,” concluded Marc Uszynski, CEO at DOSIsoft, “We are convinced that dosimetry will play a crucial role in the future radiotheranostics solutions. The achievement of these missions is completely in line with the strategic development of DOSIsoft PLANET® Dose software - multi-radionuclide and personalized voxel-based dosimetry platform - to streamline and harmonize new radiotheranostics processes for optimized standard clinical practice.”
About Thera4Care
Thera4Care brings together partners from 14 European countries and the United States. The consortium's main academic partners include Università Cattolica del Sacro Cuore (UCSC) & Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Italy), Erasmus University (Netherlands), Jules Bordet Institute (Belgium), UniKlinik Essen (Germany), Gregorio Maranon General University Hospital (Spain) and Institut de Cancérologie de l'Ouest (France).
Thera4Care is funded by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101172788. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, Atley Solutions, Curasight, Dosisoft, Minerva Imaging, Perspective Therapeutics, and Tethera.
The grant agreement was signed on October 1, 2024, and runs through the next five years. For more information, please visit the IHI website or Thera4Care project website.
About PLANET®
PLANET® Onco Dose Edition 3 is developed by DOSIsoft SA in France. Version 3.1 is FDA 510(k) cleared for 90Y Post-implantation and IIb class CE marked (MDD). The product or certain features may or may not be available for clinical use in any particular country.
About DOSIsoft
Founded in 2002, DOSIsoft designs, develops & delivers patient-specific imaging & dosimetry software solutions in Radiation Oncology & Nuclear Medicine to improve cancer patient safety & treatment quality. More than 20 years of innovation and R&D investments have led to world leading software used in over 600 hospital centers in 60 countries. Spin-off between Gustave Roussy and Institut Curie, DOSIsoft constantly innovates in partnership with the major cancer institutes and research centers in the world. www.dosisoft.com
Back to HCB News
